Roth Boosts PT on Concert Pharma (CNCE) to $22 Following; Deuterium Platform, Partnerships Will Bolster Gains
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Concert Pharmaceuticals Reports First Quarter 2015 Financial Results
May 8, 2015 7:00 AM EDTConference Call Scheduled Today at 8:30 a.m. EDT
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2015.
Concert ended the first quarter with a strong balance sheet and the financial resources to continue advancing our portfolio of product candidates, said Roger Tung,... More
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
May 7, 2015 4:05 PM EDTPhase 1 Results Support Further Evaluation of JZP-386
DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)-- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)... More
